PF-4708671 Licensed and Manufactured by Pfizer

Catalog No.S2163

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PF-4708671 Chemical Structure

PF-4708671 Chemical Structure
Molecular Weight: 390.41

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PF-4708671 is available in the following compound libraries:

Product Information

  • Compare S6 Kinase Inhibitors
    Compare S6 Kinase Products
  • Research Area

Product Description

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets p70 S6K1 [1]
(Cell-free assay)
IC50 160 nM
In vitro PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BHT-101M3jm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTBwOEKwNlQh|ryPMonaV2FPT0WU
UACC-893NV3OXm8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTpTWM2OD13LkG5PFg3KM7:TR?=MX\TRW5ITVJ?
A427NH3UXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETk[4VKSzVyPUWuO|I2PjdizszNNYq4VmZ6W0GQR1XS
OCUB-MMlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPUeWI2UUN3ME22MlY3OTB{IN88US=>NWnueoF3W0GQR1XS
SW684M3fHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\ESFdvUUN3ME23MlUzOjZ6IN88US=>Mn\CV2FPT0WU
SK-LMS-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTlwMEGzNFIh|ryPNGPSU|FUSU6JRWK=
CP50-MEL-BNFjyW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXETWM2OD17LkOwOFE6KM7:TR?=M13lc3NCVkeHUh?=
NCI-H1651M3jJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LLOmlEPTB;MUCuNFI4PiEQvF2=MnThV2FPT0WU
ABC-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nmfmlEPTB;MUCuNVA{PyEQvF2=NXHSVpJ4W0GQR1XS
OE19NYDEVlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXuyRmJIUUN3ME2xNE4yPzN|IN88US=>MmjYV2FPT0WU
DSH1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYi0e|Y1UUN3ME2xNE45QDd7IN88US=>MULTRW5ITVJ?
SW13NV7XNHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HVR2lEPTB;MUGuPVMyQSEQvF2=M4HJfnNCVkeHUh?=
MDA-MB-453MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrUcnF{UUN3ME2xNk4yPjB|IN88US=>NHG2dpVUSU6JRWK=
647-VNX;hVFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTF{LkO1PFIh|ryPNH7tT5hUSU6JRWK=
NCI-H2342NU\sN3ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvMT|ZKSzVyPUGyMlM6QTVizszNMlHWV2FPT0WU
LB2241-RCCMnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3neGdqUUN3ME2xNk42Pzd7IN88US=>MVvTRW5ITVJ?
UACC-257MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLqXlVZUUN3ME2xN{41PDV|IN88US=>M13EcXNCVkeHUh?=
NCI-H661M4\2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTF|Lk[0OFkh|ryPM1TmdHNCVkeHUh?=
FADUNGqwTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTF|Lk[5PVIh|ryPMnzJV2FPT0WU
A2780M1zQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;qPVBKSzVyPUGzMlgxPDFizszNNHrBXW1USU6JRWK=
NCI-H1793MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTF2LkSwPFUh|ryPMXzTRW5ITVJ?
TE-8NHywSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHScYpKSzVyPUG1MlM1PjVizszNMk\GV2FPT0WU
HGC-27M4HFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYWw[2ZIUUN3ME2xOk4yPjR2IN88US=>NYXYO3FxW0GQR1XS
MMAC-SFNULVR2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTF5LkO3Nlch|ryPNHTRU2xUSU6JRWK=
Calu-6NWfwemFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnhTWM2OD1zOD6xOVE{KM7:TR?=NFXaVmhUSU6JRWK=
HUTU-80NVLFfFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTF6LkO5OVkh|ryPNV7GeY5VW0GQR1XS
SASM1PYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfITWM2OD1zOD62OFU2KM7:TR?=MX3TRW5ITVJ?
IST-MES1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rsO2lEPTB;MUiuOlUxQCEQvF2=MoHxV2FPT0WU
C3ANICxXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXWTWM2OD1zOD63PVE6KM7:TR?=NEfnPWlUSU6JRWK=
ES3MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1yyZWlEPTB;MUiuPFM3PCEQvF2=M2nRTXNCVkeHUh?=
HSC-2NYjUTVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnjTWM2OD1zOT62OVQyKM7:TR?=MWfTRW5ITVJ?
T47DM2HyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPud2lLUUN3ME2yNE4yPDh3IN88US=>NH;nTXlUSU6JRWK=
EW-7MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjRO3JKSzVyPUKwMlg2QDhizszNNX74OHZ5W0GQR1XS
LN-405NU\Z[257T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rYUGlEPTB;MkCuPFk3PSEQvF2=M4HnTHNCVkeHUh?=
U031MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH6wTItKSzVyPUKxMlQ5ODJizszNMYXTRW5ITVJ?
A549MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vvdmlEPTB;MkGuPFQ6OSEQvF2=MYLTRW5ITVJ?
RMG-INGTkcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;0[oFFUUN3ME2yNk4zPjZ6IN88US=>MoP2V2FPT0WU
BT-474MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkG4TWM2OD1{Mj62OVUyKM7:TR?=M37qdXNCVkeHUh?=
NB69NXzjc5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJ|LkG1NkDPxE1?NULJ[lByW0GQR1XS
NB7NIjiUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTJ2LkG4PEDPxE1?Mm\5V2FPT0WU
HCC1569M1LuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfsdZNKSzVyPUK0MlYyOjVizszNM2n6bHNCVkeHUh?=
MEL-JUSOMkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXON2RKSzVyPUK0MlY6ODhizszNM4CxbHNCVkeHUh?=
MDA-MB-175-VIIMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTJ3LkK1NVch|ryPNXnoRmZKW0GQR1XS
HCC1419NYrxNXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\BTWM2OD1{NT62NFA{KM7:TR?=MWnTRW5ITVJ?
Ca9-22NHjZTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHITWM2OD1{NT62OFMzKM7:TR?=MlrYV2FPT0WU
KGNNI\abphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInw[2NKSzVyPUK1Mlc2PDdizszNMV7TRW5ITVJ?
LB373-MEL-DM2LsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDLTWM2OD1{Nj6xPVM5KM7:TR?=NXLM[2tzW0GQR1XS
NCI-H1755M3PJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTJ4Lki4OFEh|ryPNHvaVlJUSU6JRWK=
D-423MGNFPxOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTO[mY6UUN3ME2yO{4xPzF3IN88US=>MmKwV2FPT0WU
DK-MGM2PXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3L1b2lEPTB;MkiuO|g1PiEQvF2=MoDqV2FPT0WU
NCI-H1623Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILUeHZKSzVyPUK4Mlg{PDJizszNMUnTRW5ITVJ?
KU-19-19NVSwNIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfZdWVuUUN3ME2yPE46QTVizszNMn7MV2FPT0WU
C-33-AMlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETz[I9KSzVyPUK5MlIyQThizszNMn6xV2FPT0WU
SCC-4NWns[INsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3admZKSzVyPUOwMlM{PTRizszNNVfiS2NLW0GQR1XS
MG-63MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3oW29KSzVyPUOwMlU6QTRizszNNHLZTJVUSU6JRWK=
LNCaP-Clone-FGCNWXqVnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXob3ZKSzVyPUOxMlQ6OjFizszNM4DoSHNCVkeHUh?=
CAPAN-1NY\zbGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTNzLkWyPFYh|ryPMoXEV2FPT0WU
GI-ME-NMkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTNzLkWzOVMh|ryPMYTTRW5ITVJ?
RERF-LC-MSNXfsRYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXPTWM2OD1|Mj62O|Q4KM7:TR?=MXvTRW5ITVJ?
KLEMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17RO2lEPTB;M{OuOFM{PCEQvF2=M3nEfXNCVkeHUh?=
KNS-81-FDMn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTN|LkWwNFgh|ryPM2TqXHNCVkeHUh?=
DOKNWfHc4pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTN2Lk[2NVIh|ryPNFLuXIhUSU6JRWK=
ACHNNVj0elF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTN3LkG1PFgh|ryPM3HSfHNCVkeHUh?=
KYSE-520NV3vXVQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\KZ2ZKSzVyPUO1MlI{PjFizszNM4O5W3NCVkeHUh?=
SBC-5NYDyNXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnnZphIUUN3ME2zOU42OTF4IN88US=>MWfTRW5ITVJ?
NCI-H28MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPjTWM2OD1|NT62Olk2KM7:TR?=NHvMb5pUSU6JRWK=
ES7MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEW0XJFKSzVyPUO2MlIzPDlizszNNGn0SJFUSU6JRWK=
A172MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHjTWdtUUN3ME2zOk41OTh5IN88US=>M3XkTHNCVkeHUh?=
UM-UC-3NXLsPFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3JTWM2OD1|Nz64O|Q3KM7:TR?=M1vQcXNCVkeHUh?=
LXF-289M4X2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLGXHJyUUN3ME2zPE4xODR5IN88US=>M2\uTXNCVkeHUh?=
KP-4MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjQ[JM1UUN3ME2zPE41PzN7IN88US=>MkO2V2FPT0WU
TE-1MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\6[Jh1UUN3ME2zPU43PTh7IN88US=>NYn3NFE4W0GQR1XS
G-402NITyS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjL[4tlUUN3ME20NE4xPjFizszNMYPTRW5ITVJ?
786-0M3jzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUO5NmFCUUN3ME20NE46ODl4IN88US=>NVvnSnl6W0GQR1XS
K5MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vrU2lEPTB;NEGuN|Y5PiEQvF2=NHrmRmJUSU6JRWK=
SK-N-DZNHrkOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7QTWM2OD12MT6zPFI{KM7:TR?=MX;TRW5ITVJ?
OVCAR-4MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jJNmlEPTB;NEGuO|U3QCEQvF2=NWTBZmg1W0GQR1XS
T84NVjmXohKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPPRm1KSzVyPUSyMlEzPjNizszNM2HBeHNCVkeHUh?=
GCIYMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHQeIZ6UUN3ME20N{4xQDB|IN88US=>Ml;OV2FPT0WU
BB49-HNCM2jBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDiZ2pbUUN3ME20N{4{OzR6IN88US=>MX;TRW5ITVJ?
SNU-C2BNX31WIFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4H1Z2lEPTB;NEOuOlQ{PiEQvF2=NGGx[2hUSU6JRWK=
TE-6NYHIW5BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjBTWM2OD12Mz64PFk1KM7:TR?=NUDRXYNjW0GQR1XS
23132-87NYTrT2dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUn2eWNiUUN3ME20OE4zQTd6IN88US=>NFLJOXpUSU6JRWK=
DMS-53MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrQVYtKSzVyPUS0MlM{QDRizszNMXHTRW5ITVJ?
ONS-76MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\pXYVKSzVyPUS0Mlc3PjFizszNMULTRW5ITVJ?
DMS-273NYDRSXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1S3W2lEPTB;NESuPVQ{KM7:TR?=NW\YNmxpW0GQR1XS
COLO-824MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEi1XppKSzVyPUS1Mlg4PzVizszNM{nXcXNCVkeHUh?=
DMS-114MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjMSGdrUUN3ME20OU45QTJ5IN88US=>M3fvTXNCVkeHUh?=
YKG-1NFezS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2W4RWlEPTB;NE[uNFM2PSEQvF2=NE\WTFFUSU6JRWK=
RH-18NWrGTmJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7CTWM2OD12Nj6zO|M{KM7:TR?=MXXTRW5ITVJ?
NCI-H1355MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTR4Lk[xPEDPxE1?NVXWbmQ6W0GQR1XS
NCI-H2170M3zPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFy3[5FKSzVyPUS3Mlc2QDRizszNM3HH[3NCVkeHUh?=
OC-314NWj6Z5ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV6zNFRjUUN3ME20O{45PDd6IN88US=>NUnjRYQ6W0GQR1XS
NCI-H2030NILpbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;4OZVKSzVyPUS3Mlg6ODZizszNNIHCV4lUSU6JRWK=
22RV1M1nu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTlRZk{UUN3ME20O{46ODF3IN88US=>NGXlNZJUSU6JRWK=
G-401M2rzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTR6LkS0NVUh|ryPNET1S5pUSU6JRWK=
YAPCNGPTdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTR7LkiwO|Mh|ryPMY\TRW5ITVJ?
SW1573MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorOTWM2OD13MD6yOFM2KM7:TR?=NFjLU2VUSU6JRWK=
COLO-792MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\KVHpPUUN3ME21NE43OjN5IN88US=>MV3TRW5ITVJ?
KNS-62NWfWdFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrMe5pKSzVyPUWwMlc2ODhizszNM2fhVnNCVkeHUh?=
NB5NYDmRVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4G5NWlEPTB;NUGuOFUxQSEQvF2=NV3Zd3liW0GQR1XS
CP66-MELNWn6WItxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTVzLk[0NFgh|ryPNUPzW5NIW0GQR1XS
CaR-1NYPLVWExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHQRWxKSzVyPUWyMlA3ODZizszNNYfvS25JW0GQR1XS
CAL-54M2faNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLRdmVKSzVyPUWyMlEyODJizszNMWPTRW5ITVJ?
8305CNI\4[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HST2lEPTB;NUKuN|E2KM7:TR?=M1XCS3NCVkeHUh?=
Calu-3Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3iWlJKSzVyPUWyMlM4OzNizszNMX;TRW5ITVJ?
AU565MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvxTWM2OD13Mj61OVA6KM7:TR?=M2nqVXNCVkeHUh?=
CW-2MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jqXWlEPTB;NUKuPFY2PCEQvF2=NGToVFZUSU6JRWK=
BENNXjIbnZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHjTWM2OD13Mz63PFYzKM7:TR?=NEL5OoxUSU6JRWK=
NCI-H1975M2mycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPIO|dCUUN3ME21N{45QTZ4IN88US=>NUjmOZYyW0GQR1XS
HCT-116NWTh[WF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTV2LkCzNlch|ryPMmf0V2FPT0WU
SH-4NHzGdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoraTWM2OD13ND6xN|gh|ryPNV:5XYFHW0GQR1XS
NCI-H1693M1\JVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUP4ZoZPUUN3ME21OE4zOTB|IN88US=>MnnHV2FPT0WU
BPH-1NIWyZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXe1eZd3UUN3ME21OU4zQDl{IN88US=>NF3jbYVUSU6JRWK=
CAMA-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jIW2lEPTB;NUWuPFEyPiEQvF2=MVHTRW5ITVJ?
A388MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1P3VGlEPTB;NU[uNFk5PSEQvF2=MkfBV2FPT0WU
C2BBe1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHNSIZKSzVyPUW2MlI3OzRizszNNVLOXJZSW0GQR1XS
GAMGNWTNOWJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\DZ|ZvUUN3ME21Ok42QTV3IN88US=>NVPYWIU3W0GQR1XS
MKN28NF;QNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrGTWM2OD13Nj64NFE{KM7:TR?=NIrnbpNUSU6JRWK=
VA-ES-BJNF\YWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjIfHBKSzVyPUW2Mlg4PDVizszNNX7PelBwW0GQR1XS
HuCCT1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPWSW5KSzVyPUW3MlA1QTJizszNNVHHWHg4W0GQR1XS
BFTC-905NV3v[o5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;HV4lKSzVyPUW3MlI5QThizszNMkPzV2FPT0WU
LS-123NUHTOm9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDObGpjUUN3ME21O{42PjZ6IN88US=>NHHUZ49USU6JRWK=
LB996-RCCM2r3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVr6RoNoUUN3ME21PE4xOjh5IN88US=>MlHwV2FPT0WU
NCI-H1048M374cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4r1VmlEPTB;NUiuNlE5QCEQvF2=NHn2WGtUSU6JRWK=
COR-L105M{XvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDoTWM2OD13OD63N|M4KM7:TR?=MmqyV2FPT0WU
OVCAR-8NVfFUHduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\JemlEPTB;NUmuNVcyPiEQvF2=MV7TRW5ITVJ?
SK-N-FIMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTV7LkOyNFch|ryPMVHTRW5ITVJ?
MES-SAMnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LjfGlEPTB;NUmuOFUxQSEQvF2=MnLEV2FPT0WU
SCC-9M3u2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlf3TWM2OD13OT60O|U{KM7:TR?=MlXRV2FPT0WU
EFO-27NWjnVYtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTV7Lkm0N{DPxE1?MmK2V2FPT0WU
GT3TKBMlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYewTIcyUUN3ME22NE43ODR6IN88US=>M{DMTHNCVkeHUh?=
HCC38MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjDW2pKSzVyPU[xMlQ{PzlizszNMkjvV2FPT0WU
MLMANGDwU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTOepFKSzVyPU[xMlYyPjNizszNMV\TRW5ITVJ?
D-566MGNIL1UVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n0T2lEPTB;NkOuOVIzPCEQvF2=M1vOcHNCVkeHUh?=
SF295NXnvb4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnv0TWM2OD14Mz62OlU2KM7:TR?=MoPjV2FPT0WU
ES4NVO0TmNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrNXZlZUUN3ME22OE41PzF7IN88US=>NFjxUoRUSU6JRWK=
CAKI-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17MTWlEPTB;NkSuOVczOSEQvF2=MlzGV2FPT0WU
OAW-28NIXEUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfReplmUUN3ME22OE46PjR5IN88US=>NF3HUnRUSU6JRWK=
NCI-H460Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnsR5hPUUN3ME22OU4xQDl5IN88US=>MoHjV2FPT0WU
JARNEXIRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTZ3LkW1NVYh|ryPM1Hj[nNCVkeHUh?=
SNU-449NY\nfWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEO0S3BKSzVyPU[1Mlc3OTZizszNMoLwV2FPT0WU
D-392MGMmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTZ3Lkm0N|Qh|ryPMkTKV2FPT0WU
EW-22NGn1fGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnKzTWM2OD14Nj6zPVUh|ryPNIXqOZZUSU6JRWK=
GCTMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkT2TWM2OD14Nz6wOFQ{KM7:TR?=NGnIW4xUSU6JRWK=
NOS-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTZ5Lk[4Olch|ryPMW\TRW5ITVJ?
RH-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33sWWlEPTB;NkiuOVU2QSEQvF2=M{\ScnNCVkeHUh?=
HuH-7M1LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fRbGlEPTB;NkmuNVAxOiEQvF2=MnXKV2FPT0WU
NUGC-3MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELnfFJKSzVyPUewMlk3PDRizszNMVnTRW5ITVJ?
IST-SL1Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTdzLkKzNlQh|ryPNEXQeJJUSU6JRWK=
SHP-77MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XndmlEPTB;N{KuNVE6KM7:TR?=M4PUSXNCVkeHUh?=
SW1116MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTd{LkG0NFch|ryPMVfTRW5ITVJ?
LK-2M1\obWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI[4VFhKSzVyPUeyMlg3OTJizszNMVPTRW5ITVJ?
U-2-OSMlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPURo06UUN3ME23N{4yQDJ6IN88US=>MWrTRW5ITVJ?
KYSE-150Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHURZVSUUN3ME23N{43OTF6IN88US=>MVPTRW5ITVJ?
U251MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPpTWM2OD15Mz64NVY5KM7:TR?=NYftO4N3W0GQR1XS
HT-1080M1vmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXTTWM2OD15ND6yOVc1KM7:TR?=NFrwXFRUSU6JRWK=
NCI-H1437M3G5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3m4[2lEPTB;N{SuOlMzPiEQvF2=NXPCdIZkW0GQR1XS
HPAF-IINHP3TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfTOZdWUUN3ME23OE43PDF3IN88US=>MnrZV2FPT0WU
BeckerNFz6U|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrCOZJzUUN3ME23OU4yOTB3IN88US=>MVLTRW5ITVJ?
PANC-10-05NEe1VFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTd3LkK4OlUh|ryPNVLZephNW0GQR1XS
TYK-nuNXf4XZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;uTWlEPTB;N{WuN|ExOiEQvF2=MoXIV2FPT0WU
SKG-IIIaM{PFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPVd|FKSzVyPUe1MlM{PDFizszNMVTTRW5ITVJ?
NCI-H1993M1vNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDETWM2OD15NT63N|k4KM7:TR?=MXLTRW5ITVJ?
S-117NGTqZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLuTWM2OD15NT63OVUh|ryPNEjOdmpUSU6JRWK=
HuO9MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrQXYQxUUN3ME23Ok4xODR6IN88US=>MoHOV2FPT0WU
CAL-51NXTSUW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmP4TWM2OD15Nj6xNFA3KM7:TR?=NXnDd25TW0GQR1XS
BT-20NGnYXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTd4LkKxOlgh|ryPNIHZVYJUSU6JRWK=
LB831-BLCMmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvOVYJKSzVyPUe2MlMzOTdizszNM3vWRXNCVkeHUh?=
LB1047-RCCM3\OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnH4TWM2OD15Nj63OlE6KM7:TR?=M{i1bnNCVkeHUh?=
ES8MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3aOJRKSzVyPUe4MlAxPzNizszNMoTDV2FPT0WU
UMC-11MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XoSGlEPTB;N{iuNFg5PCEQvF2=MVjTRW5ITVJ?
NCI-H226MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HSbmlEPTB;N{iuNVMyPSEQvF2=MVLTRW5ITVJ?
IGROV-1MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\EUoMyUUN3ME23PE42PTVizszNNEL0eXhUSU6JRWK=
BHYNVzFWpVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIS1fGNKSzVyPUe5MlU6PiEQvF2=M2\FeHNCVkeHUh?=
MKN45M1T1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn6zTWM2OD16MD6zNVc1KM7:TR?=MnXlV2FPT0WU
IA-LMNVX2UHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjSTWM2OD16MD6zOVEyKM7:TR?=M13HZXNCVkeHUh?=
WM-115MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmKwTWM2OD16MT60NVE1KM7:TR?=NFnmWVlUSU6JRWK=
VMRC-RCZM4f5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYG3d29[UUN3ME24NU41PDJ3IN88US=>M2XEOnNCVkeHUh?=
NCI-H2291MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGS3NGdKSzVyPUixMlY5PDJizszNNIHUNHlUSU6JRWK=
MCF7NYLBfotjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIG0WJBKSzVyPUizMlI5QTdizszNM{jZ[XNCVkeHUh?=
639-VM1vpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvMdXNKSzVyPUi0MlYyOjlizszNMoH2V2FPT0WU
RT4NWfrNJdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrDRpU3UUN3ME24OU4zPDB|IN88US=>MoKzV2FPT0WU
NCI-H2405NITQTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfOWJpjUUN3ME24OU4zQTl5IN88US=>M4rJZXNCVkeHUh?=
CAL-33MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYe3e21qUUN3ME24OU43OzF3IN88US=>MoPpV2FPT0WU
BT-549NGXGRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTh3LkmzPFIh|ryPM2L3[HNCVkeHUh?=
HT-1197NYrveo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTh6LkGwO|ch|ryPM4frPXNCVkeHUh?=
G-361MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHhRmU2UUN3ME24PE4yPDd2IN88US=>NGLUSXdUSU6JRWK=
LS-411NMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\PUFlKSzVyPUi5MlM{QDhizszNMof6V2FPT0WU
HT-144MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLhV25KSzVyPUi5MlU6QTJizszNNWSzPHoyW0GQR1XS
DJM-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTh7Lki4OFUh|ryPNIDZZ41USU6JRWK=
CAL-12TNXOxO2FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjjb2lpUUN3ME25NE44QDl3IN88US=>NXfYTVU{W0GQR1XS
MKN7MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTlzLkO1OVEh|ryPNFj3e3lUSU6JRWK=
HuP-T3M2jVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTl4LkGwNFQh|ryPMWfTRW5ITVJ?
SK-MG-1MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7TTWM2OD17Nj6xN|Q5KM7:TR?=MXTTRW5ITVJ?
NCI-H2347MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nIW2lEPTB;OUiuNVA1OiEQvF2=M3ryZXNCVkeHUh?=
SW872NUHV[lZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUK4V4h2UUN3ME2xNFAvPDV4IN88US=>NFTwTZhUSU6JRWK=
COLO-829M{\KdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLrSm41UUN3ME2xNFAvPTV|IN88US=>M4HY[nNCVkeHUh?=
MC-IXCMmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\VbplMUUN3ME2xNFAvPjF3IN88US=>M3X3dHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase activity assays For selectivity IC50 assays, purified active GST–S6K1, GST–S6K2, His–MSK1 (residues 2–802), His–RSK1 (residues 1–735) and His–RSK2 (residues 2–740) (0.5 units/mL) are assayed for 30 min at 30 °C in a 50 μL assay mixture in buffer A containing either 30 μM Crosstide (GRPRTSSFAEG, for S6K1, S6K2 and MSK1) or 30 μM Long S6 (KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, for RSK1 and RSK2), 10 mM magnesium acetate and 100 μM [γ- 32P]ATP. Reactions are terminated and the incorporation of [γ-32P]phosphate into the peptide substrate is determined by applying the reaction mixture on to P81 phosphocellulose paper and scintillation counting after washing the papers in phosphoric acid. One unit of activity is defined as that which catalysed the incorporation of 1 nmol of [32P]phosphate into the substrate. To determine the Ki for PF-4708671, full-length recombinant S6K1 is added to a final concentration of 5 nM to Omnia assay buffer containing various concentrations of compound. The reaction is run for 60 min at 30 °C in a 50 μL assay volume. The fluorescence of the peptide is monitored at an excitation wavelength of 360 nm and an emission wavelength of 485 nm. The rate of the reaction at each compound concentration is normalized to the DMSO control rate, and this normalized rate against concentration is fitted to the Morrison tight-binding equation for a competitive inhibitor to provide the true Ki. In order to assay S6K activity in HEK-293 cell lysates, cells are lysed in Tris lysis buffer. Lysate (0.5 mg) is incubated with 5 μg of S6K antibody conjugated to Protein G–Sepharose for 1 h at 4 °C on a vibrating platform. Immunoprecipitates are washed twice with lysis buffer and twice with buffer A, and kinase activity is assayed exactly as described above using the Crosstide peptide.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Chemical Information

Download PF-4708671 SDF
Molecular Weight (MW) 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1H-Benzimidazole, 2-[[4-(5-ethyl-4-pyrimidinyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related S6 Kinase Products

  • LY2584702

    LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • LY2584702 Tosylate

    LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • BI-D1870

    BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Recently Viewed Items

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us